Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.

Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for antiretroviral therapy (ART) could benefit many people with HIV (PWH). However, its impact will largely be determined by providers' willingness to prescribe it and PWH's willingness to take it. This study explores the perceived barr...

Descripción completa

Detalles Bibliográficos
Publicado en:AIDS Patient Care & STDs Vol. 38; no. 6; pp. 275 - 286
Autores principales: Fisk-Hoffman, Rebecca J., Ranger, Sashaun S., Gracy, Abigail, Gracy, Hannah, Manavalan, Preeti, Widmeyer, Maya, Leeman, Robert F., Cook, Robert L., Canidate, Shantrel
Formato: research tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Jun2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178133110&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 178133110
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10872914
        33C
      jtl: AIDS Patient Care & STDs
      issn: 10872914
      maglogo: N
    pubinfo:
      dt: Jun2024
      vid: 38
      iid: 6
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        178133110
        178133110
        178133110
        10.1089/apc.2024.0067
        178133110
      ppf: 275
      ppct: 11
      formats:
      tig:
        atl: Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
      aug:
        au:
          Fisk-Hoffman, Rebecca J.
          Ranger, Sashaun S.
          Gracy, Abigail
          Gracy, Hannah
          Manavalan, Preeti
          Widmeyer, Maya
          Leeman, Robert F.
          Cook, Robert L.
          Canidate, Shantrel
        affil: Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, Gainesville, Florida, USA.
      sug:
        subj:
          Attitude of Health Personnel
          HIV-Positive Persons Psychosocial Factors
          Patient Attitudes
          Rilpivirine Therapeutic Use
          HIV Infections Drug Therapy
          Anti-HIV Agents
          Program Implementation
          Injections
          Human
          Adolescence
          Adult
          Middle Age
          Cisgender Persons
          Male
          Female
          Florida
          Funding Source
          Health Personnel
          HIV Infections Epidemiology
          Semi-Structured Interview
          White Persons
          African Americans
          Hispanic Americans
          Outpatient Service
          Thematic Analysis
          HIV Integrase Inhibitors
          Drug Resistance
          Transportation
          Stigma
          Health Services Accessibility
          Insurance, Health
          Personnel Shortage
          Workload
          Qualitative Studies
          Implementation Science
          Conceptual Framework
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for antiretroviral therapy (ART) could benefit many people with HIV (PWH). However, its impact will largely be determined by providers' willingness to prescribe it and PWH's willingness to take it. This study explores the perceived barriers and facilitators of LAI CAB/RPV implementation among PWH and HIV care providers in Florida, a high prevalence setting. Semi-structured qualitative interviews were conducted in English with 16 PWH (50% non-Hispanic White, 50% cis men, and 94% on oral ART) and 11 providers (27% non-Hispanic Black, 27% Hispanic, 73% cis women, and 64% prescribed LAI CAB/RPV) throughout the state. Recruitment occurred between October 2022 and October 2023 from HIV clinics. Interviews were recorded, professionally transcribed, and then double coded using thematic analysis. The Consolidated Framework for Implementation Research guided the interview guide and coding. While PWH viewed LAI CAB/RPV as effective, predominant barriers included administration via injection, challenges of attending more clinic visits, and a feeling that this made HIV the center of one's life. Providers additionally expressed concerns about the development of integrase resistance. Barriers noted by PWH and providers outside of the clinic included transportation, stigma, access inequities, and payor issues. Within clinics, providers identified the need for extra staffing and the increased burden on existing staff as barriers. These barriers decreased the perceived need for LAI CAB/RPV among PWH and providers, especially with the high effectiveness of oral ART. Many of the identified barriers occur outside of the clinic and will likely apply to other novel long-acting ART options.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N